Journal article

Identification of 3-aminothieno[2,3-b]pyridine-2-carboxamides and 4-aminobenzothieno[3,2-d]pyrimidines as LIMK1 inhibitors

BE Sleebs, A Levit, IP Street, H Falk, T Hammonds, AC Wong, MD Charles, MF Olson, JB Baell

Medchemcomm | ROYAL SOC CHEMISTRY | Published : 2011

Abstract

A high throughput chemical screening campaign has led to the identification of 3-aminobenzo[b]thiophene-2-carboxamides as LIMK1 inhibitors. Evolution of bicyclic hits to the tricyclic 4-aminobenzothieno[3,2-d]pyrimidine, using a traditional medicinal chemistry SAR guided approach, resulted in a significant increase in potency. Further elaboration has seen the 7-phenyl-4- aminobenzothieno[3,2-d]pyrimidine emerge as a LIMK1 inhibitor lead candidate. © The Royal Society of Chemistry 2011.

University of Melbourne Researchers

Grants

Awarded by NHMRC IRIISS


Funding Acknowledgements

The authors acknowledge the financial support of the Cancer Therapeutics CRC, established and supported under the Australian Government's Cooperative Research Centres Program; NHMRC IRIISS grant number 361646 and Victorian State Government OIS grant.